看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | -0.3x - -0.3x | -0.3x |
| Selected Fwd EBITDA Multiple | -0.2x - -0.2x | -0.2x |
| Fair Value | €6.75 - €6.85 | €6.80 |
| Upside | -18.3% - -17.1% | -17.7% |
| Benchmarks | Ticker | Full Ticker |
| BioMarin Pharmaceutical Inc. | BMRN | NasdaqGS:BMRN |
| Ionis Pharmaceuticals, Inc. | IONS | NasdaqGS:IONS |
| BioCryst Pharmaceuticals, Inc. | BCRX | NasdaqGS:BCRX |
| KalVista Pharmaceuticals, Inc. | KALV | NasdaqGM:KALV |
| CSL Limited | CMXH.F | PINC:CMXH.F |
| Intellia Therapeutics, Inc. | 38I | DB:38I |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| BMRN | IONS | BCRX | KALV | CMXH.F | 38I | ||
| NasdaqGS:BMRN | NasdaqGS:IONS | NasdaqGS:BCRX | NasdaqGM:KALV | PINC:CMXH.F | DB:38I | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | 332.0% | NM- | NM- | NM- | 10.4% | NM- | |
| 3Y CAGR | 170.4% | NM- | NM- | NM- | 10.2% | NM- | |
| Latest Twelve Months | 129.7% | -29.4% | 101.8% | -46.8% | 5.5% | -3.5% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 7.3% | -32.1% | -157.8% | -739.0% | 32.1% | -743.1% | |
| Prior Fiscal Year | 12.0% | -40.7% | -28.9% | NA | 30.4% | -1395.8% | |
| Latest Fiscal Year | 23.4% | -65.7% | 0.4% | NA | 31.2% | -905.3% | |
| Latest Twelve Months | 23.4% | -64.3% | 0.4% | NA | 31.7% | -905.3% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 3.75x | 7.02x | 5.30x | NA | 6.10x | -0.41x | |
| EV / LTM EBITDA | 16.0x | -10.9x | 1378.4x | -2.4x | 19.3x | 0.0x | |
| EV / LTM EBIT | 18.8x | -10.7x | -1867.7x | -2.3x | 22.9x | 0.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -10.9x | 16.0x | 1378.4x | ||||
| Historical EV / LTM EBITDA | -32.8x | -5.1x | 0.0x | ||||
| Selected EV / LTM EBITDA | -0.3x | -0.3x | -0.3x | ||||
| (x) LTM EBITDA | (524) | (524) | (524) | ||||
| (=) Implied Enterprise Value | 132 | 139 | 146 | ||||
| (-) Non-shareholder Claims * | 678 | 678 | 678 | ||||
| (=) Equity Value | 811 | 818 | 825 | ||||
| (/) Shares Outstanding | 103.5 | 103.5 | 103.5 | ||||
| Implied Value Range | 7.83 | 7.90 | 7.97 | ||||
| FX Rate: USD/EUR | 1.1 | 1.1 | 1.1 | Market Price | |||
| Implied Value Range (Trading Cur) | 6.93 | 6.99 | 7.05 | 8.26 | |||
| Upside / (Downside) | -16.1% | -15.4% | -14.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | BMRN | IONS | BCRX | KALV | CMXH.F | 38I | |
| Enterprise Value | 10,864 | 4,997 | 2,368 | 426 | 88,371 | 289 | |
| (+) Cash & Short Term Investments | 1,138 | 2,148 | 321 | 253 | 1,524 | 602 | |
| (+) Investments & Other | 528 | 41 | 20 | 0 | 0 | 287 | |
| (-) Debt | (634) | (1,969) | (841) | (6) | (11,964) | (210) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | (1,987) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 11,896 | 5,217 | 1,868 | 674 | 75,944 | 967 | |
| (/) Shares Outstanding | 191.8 | 159.2 | 209.2 | 49.7 | 484.2 | 103.5 | |
| Implied Stock Price | 62.03 | 32.78 | 8.93 | 13.55 | 156.84 | 9.34 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.13 | |
| Implied Stock Price (Trading Cur) | 62.03 | 32.78 | 8.93 | 13.55 | 156.84 | 8.26 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.13 | |